Adam A Capoferri
Overview
Explore the profile of Adam A Capoferri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1884
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mumby M, Prodger J, Hackman J, Saraf S, Zhu X, Ferreira R, et al.
Lancet Microbe
. 2025 Mar;
:101018.
PMID: 40088911
Background: The persistence of a replication-competent latent viral reservoir (RC-LVR) during antiretroviral therapy (ART) is a barrier to the development of a cure for HIV-1, but the role of viral...
2.
Katusiime M, Neer V, Guo S, Patro S, Wang W, Luke B, et al.
J Clin Invest
. 2025 Mar;
PMID: 40048262
Background: Naïve cells comprise 90% of the CD4+ T-cell population in neonates and exhibit distinct age-specific capacities for proliferation and activation. We hypothesized that HIV-infected naïve CD4+ T-cell populations in...
3.
Capoferri A, Wiegand A, Hong F, Jacobs J, Spindler J, Musick A, et al.
Proc Natl Acad Sci U S A
. 2024 Aug;
121(36):e2405210121.
PMID: 39190360
In the absence of antiretroviral therapy (ART), a subset of individuals, termed HIV controllers, have levels of plasma viremia that are orders of magnitude lower than non-controllers (NC) who are...
4.
Ferreira R, Reynolds S, Capoferri A, Baker O, Brown E, Klock E, et al.
EBioMedicine
. 2024 Mar;
102():105040.
PMID: 38485563
Background: The principal barrier to an HIV cure is the presence of the latent viral reservoir (LVR), which has been understudied in African populations. From 2018 to 2019, Uganda instituted...
5.
Rausch J, Parvez S, Pathak S, Capoferri A, Kearney M
Viruses
. 2024 Jan;
16(1).
PMID: 38257808
The principal barrier to an HIV-1 cure is the persistence of infected cells harboring replication-competent proviruses despite antiretroviral therapy (ART). HIV-1 transcriptional suppression, referred to as viral latency, is foremost...
6.
Ferreira R, Reynolds S, Capoferri A, Baker O, Brown E, Klock E, et al.
medRxiv
. 2023 Jun;
PMID: 37292785
The principal barrier to an HIV cure is the presence of a latent viral reservoir (LVR) made up primarily of latently infected resting CD4+ (rCD4) T-cells. Studies in the United...
7.
Capoferri A, Shao W, Spindler J, Coffin J, Rausch J, Kearney M
Viruses
. 2022 Jan;
14(1).
PMID: 35062308
COVID-19 vaccines were first administered on 15 December 2020, marking an important transition point for the spread of SARS-CoV-2 in the United States (U.S.). Prior to this point in time,...
8.
Capoferri A, Redd A, Gocke C, Clark L, Quinn T, Ambinder R, et al.
J Acquir Immune Defic Syndr
. 2021 Nov;
89(3):297-302.
PMID: 34753870
Background: Allogeneic bone marrow transplant (alloBMT) in people living with HIV can lead to the undetectable levels of HIV reservoirs in blood, even using highly sensitive assays. However, with antiretroviral...
9.
Capoferri A, Shao W, Spindler J, Coffin J, Rausch J, Kearney M
medRxiv
. 2021 Jun;
PMID: 34127980
One Sentence Summary: SARS-CoV-2 genetic diversity in the U.S. increased 3-fold in 2020 and 54 emergent nonsynonymous mutations were detected.
10.
Capoferri A, Redd A, Gocke C, Clark L, Ambinder R, Durand C
AIDS Res Hum Retroviruses
. 2021 Jun;
38(1):33-36.
PMID: 34107771
Allogeneic bone marrow transplant (alloBMT) with continuous antiretroviral therapy alone has not been shown to completely eradicate HIV, possibly due to HIV persistence in rare residual host cells or infection...